Skip to main content

Table 1 The different effects of oncovirus on CDK and CIKs

From: Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers

Viral pathogen

Viral Factor

HDAC/Mechanism/Effect

References

HPV

E7

p21Cip1 suppression

Shin MK et al.,2009 [33]

HPV

E7

CDK2/cyclin A activation

He W et al.,2003 [34]

HPV16

E7

block the effect of p21on (PCNA)-

Funk J et al.,1997 [35]

HPV-18 E1^E4

E1^E4

both cyclin E and cyclin A/CDK 2 activation

Ding Q et al.,2013 [36]

HPV-16

E7

Cyclin E activation- decrease in CIKs except, p21 and p16

Martin L et al.,1998 [37]

HPV

E6

Decrease in p21 and up-regulation of cyclin E/CDK2

Syrjänen SM et al.,1999 [39]

HPV31

 

cyclins A, B, and E, Cdc25c, Cdk1 and Cdk2 activation

Mighty, K.K et al.,2011 [44]

HPV18

 

Increase the levels of cytoplasmic cyclin B1 and inactivation of cyclin-dependent kinase1(Cdk1)

Wang, H.K et al.,2009 [45]

High

E7

Promotion of Cyclin A/E/ CDK2

Nguyen, C.L et al.,2008 [46], Katich, S.C et al.,2001 [48]

HTLV

 

Decrease in p21WAF1/CIP1

Moles R et al.,2015 [49]

HTLV

 

Down-regulation of p27KIP1

Cereseto A et al.,1999 [50]

HTLV-I

Tax

Cyclin A limitation

Kibler KV et al.,2001 [51]

HTLV

P30

Binding with cyclin A and cdk2, and preventing enter in S phase

Baydoun HH et al.,2010 [52]

HTLV

 

Increase in cyclin D/ CDK2 and inhibition of INK4

Grassmann R et al.,2005 [53]

HTLV

 

cyclin D2/ CDK4,6

Santiago F et al.,1999 [54]

HTLV

 

p18ink4c inactivation

Suzuki T et al.,1999 [55]

HTLV

 

CDK4

Haller K et al.,2002 [56]

EBV

EBNA3C

cyclinA/CDK2 is activation

Knight JS et al.,2004 [57]

EBV

EBNA3C

Suppression of p16/INK4a

Parker GA et al.,1996 [58, 59]

EBV

EBNA3C

Targeting of SCF/skp2 E3

Kumar P et al.,2009 [60], Iwahori S et al.,2009 [61]

EBV

EBNA3C

Repressing the repress p21WAF1/CIP1, p14ARF and p16INK4a

Tursiella ML et al.,2014 [62]

EBV

BZLF1

Increase in p21WAF1/CIP1

Sato Y et al.,2010 [63]

EBV

 

Up-regulation of cdc-2, cyclin E, D23, and cyclin D2

Hollyoake M et al., 1995 [64]

EBV

LMPA 2A and MYC

Suppress the p27

Kamonwan Fish et al.,2014 [65]

EBV

 

Increase in CDKN2A

Vo QN et al.,2002 [66]

KSHV

K-cyclin

CDK6

Li, M et al.,1997 [67]

KSHV

K-cyclin

CDK9

Chang PC et al.,2007 [68]

KSHV

v-cyclin

P27

Moore PS et al.,2001 [69]

KSHV

 

p21

Van Dross R et al.,2005 [70]

HBV

HBx

Suppression of P21

Han,J et al.,2000 [71]

HBV

HBX

cyclinA/CDK2

Bouchard M et al.,2001 [72]

HBV

HBX

Methylation of P16

Jung JK et al.,2007 [73]

HCV

HCV core

Inhibition of CDK7

Ohkawa K et al.,2004 [74]

HCV

HCV core

Activation of CDK2

Ohkawa K et al.,2004 [74]

HCV

HCV core

cyclinA, E, D1, CDK2 and CDK4

Bahnassy AA et al.,2011 [75]

HCV

NS5A

P16,P21,P57

Arima N et al.,2001 [76], Wagayama H et al.,2001 [77], Shackel NA et al.,2002 [78]

Avian Reovirus

p17

Activation of v-CDKI

Huang W et al., 2017 [79]

Avian Reovirus

P17

CDK inhibitor (V-CDKI)

Kozak R et al., 2017 [80]

Avian Reovirus

P17

v-CDKI

Chiu HC et al., 2018 [28]

Avian Reovirus

P17

suppression of CDK1/cyclin B1, CDK2/cyclin A2, CDK2/cyclin E1, and CDK6/cyclin D1 complexes by direct binding to CDKs, cyclins or complexes

Huang W et al. 2017 [79]

Avian Reovirus

P17

Suppression of the CDK7/cyclin H complex by promoting p53 and cyclin H interaction.

Huang W et al. 2017 [79]